Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, details the May 2020 FDA approval of selpercatinib, a RET inhibitor, in RET fusion positive non-small cell lung cancer (NSCLC), medullary thyroid cancer and RET fusion positive thyroid cancer following the results of the LIBRETTO-001 study (NCT03157128). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).